Research programme: alpha-1A antagonists - Johnson & Johnson

Drug Profile

Research programme: alpha-1A antagonists - Johnson & Johnson

Latest Information Update: 25 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Johnson & Johnson Pharmaceutical Research & Development LLC
  • Class
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 25 Sep 2006 Discontinued - Preclinical for Benign prostatic hyperplasia in USA (unspecified route)
  • 27 Mar 2000 Preclinical development for Benign prostatic hyperplasia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top